We are live on ! Find out more
PACB icon

Pacific Biosciences
PACB

141 hedge funds and large institutions have $432M invested in Pacific Biosciences in 2016 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 70 increasing their positions, 27 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

159% more repeat investments, than reductions

Existing positions increased: 70 | Existing positions reduced: 27

93% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 15

9% more funds holding

Funds holding: 129 → 141 (+12)

11% less capital invested

Capital invested by funds: $487M → $432M (-$54.8M)

28% less call options, than puts

Call options by funds: $4.08M | Put options by funds: $5.66M

50% less funds holding in top 10

Funds holding in top 10: 4 → 2 (-2)

Holders
141
Holders Change
+12
Holders Change %
+9.3%
% of All Funds
3.76%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.05%
New
29
Increased
70
Reduced
27
Closed
15
Calls
$4.08M
Puts
$5.66M
Net Calls
-$1.58M
Net Calls Change
-$876K

Top Buyers

1
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$22.9M
2
RCM
Raging Capital Management
New Jersey
+$15.9M
3
BM
Bridger Management
New York
+$9.91M
4
Capital World Investors
Capital World Investors
California
+$8.15M
5
Wells Fargo
Wells Fargo
California
+$8.04M

Top Sellers

1
CCM
Consonance Capital Management
New York
-$31.1M
2
EAM
EverPoint Asset Management
Connecticut
-$8.07M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$7.65M
4
Renaissance Technologies
Renaissance Technologies
New York
-$7.17M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
-$6M
Name Holding Trade Value Shares
Change 		Change in
Stake
First Trust Advisors
51
First Trust Advisors
Illinois
$900K +$1.17M +127,934 New
IA
52
IFP Advisors
Florida
$839K +$953K +104,297 +695%
Morgan Stanley
53
Morgan Stanley
New York
$828K +$227K +24,898 +27%
UBS Group
54
UBS Group
Switzerland
$798K +$967K +105,880 +1,408%
WMSA
55
Weiss Multi-Strategy Advisers
New York
$795K -$311K -34,005 -23%
VKH
56
Virtu KCG Holdings
New York
$723K +$939K +102,833 New
IHM
57
Iguana Healthcare Management
New York
$704K +$228K +25,000 +33%
AIMCA
58
Alberta Investment Management Corp (AIMCo)
Alberta, Canada
$697K +$905K +99,100 New
JGC
59
J. Goldman & Co
New York
$687K -$1.83M -200,231 -67%
CS
60
Credit Suisse
Switzerland
$680K +$249K +27,308 +39%
RhumbLine Advisers
61
RhumbLine Advisers
Massachusetts
$625K +$108K +11,802 +15%
AllianceBernstein
62
AllianceBernstein
Tennessee
$604K +$20.1K +2,200 +3%
New York State Common Retirement Fund
63
New York State Common Retirement Fund
New York
$554K +$162K +17,700 +29%
IG
64
ING Group
Netherlands
$535K -$648K -70,980 -48%
Goldman Sachs
65
Goldman Sachs
New York
$527K +$60.3K +6,605 +10%
Capital Fund Management (CFM)
66
Capital Fund Management (CFM)
France
$526K +$683K +74,800 New
ProShare Advisors
67
ProShare Advisors
Maryland
$522K +$64.5K +7,057 +11%
DM
68
Deerfield Management
New York
$444K +$576K +63,072 New
EA
69
Emerald Acquisition
Washington
$432K +$561K +61,404 New
JP Morgan Chase
70
JP Morgan Chase
New York
$386K +$232K +25,346 +86%
MLICM
71
Metropolitan Life Insurance Company (MetLife)
New York
$378K +$28.2K +3,084 +6%
Manulife (Manufacturers Life Insurance)
72
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$376K +$109K +11,920 +29%
CG
73
Cutler Group
California
$362K +$343K +37,571 +270%
AI
74
Analytic Investors
California
$356K +$462K +50,597 New
DekaBank Deutsche Girozentrale
75
DekaBank Deutsche Girozentrale
Germany
$353K +$132K +14,500 +43%
1 2
3
4 5

PACB Hedge Fund Activity: Q2 2016 in Review

141 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q2 2016, worth a combined $432M — down 11% from $487M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new PACB positions and 15 closed out — a net gain of 14 holders — while 70 added to existing stakes and 27 trimmed.

The largest buyer was Lord, Abbett & Co, adding an estimated $22.9M. The largest seller was Consonance Capital Management, cutting an estimated $31.1M.

  • 141 institutional investors held Pacific Biosciences (PACB) as of Q2 2016, up from 129 in Q1 2016.
  • Funds reported $432M of Pacific Biosciences stock for Q2 2016, down 11% quarter-over-quarter.
  • 29 funds opened new Pacific Biosciences positions in Q2 2016 and 15 closed out, a net change of +14 holders.
  • The largest Pacific Biosciences buyer in Q2 2016 was Lord, Abbett & Co, an estimated $22.9M added.
  • The largest Pacific Biosciences seller in Q2 2016 was Consonance Capital Management, an estimated $31.1M sold.

Based on aggregated 13F filings for Q2 2016.